Akeso Inc., a biopharmaceutical company incorporated in the Cayman Islands, announced on May 24, 2025, the grant of Share Options and Restricted Share Units (RSUs) to recognize the contributions of its directors and existing employees. The announcement, made in compliance with the Listing Rules of the Stock Exchange of Hong Kong, disclosed the allocation of 4,080,000 Share Options to its board members, with Dr. XIA Yu, the chairwoman and executive director, receiving the largest portion of 3,000,000 options. Additionally, 3,035,000 Share Options were distributed among other company employees. The vesting of RSUs will be contingent upon individual performance targets, specifically tailored to the functions of each grantee, such as research and development, sales, and financial performance. This strategic move aims to align the interests of the company's leadership and staff with its operational and growth objectives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.